anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Allergic rhinitis (AR) is caused by type I hypersensitivity reaction in the nasal tissues. The interaction between CD300f and its ligand ceramide suppresses immunoglobulin E (IgE)-mediated mast cell activation. However, whether CD300f inhibits the development of allergic rhinitis (AR) remains elusive. We aimed to investigate the roles of CD300f in the development of AR and the effectiveness of intranasal administration of ceramide liposomes on AR in murine models. We used ragweed pollen-induced AR models in mice. Notably, CD300f deficiency did not significantly influence the ragweed-specific IgE production, but increased the frequency of mast cell-dependent sneezing as well as the numbers of degranulated mast cells and eosinophils in the nasal tissues in our models. Similar results were also obtained for MCPT5-exprssing mast cell-specific loss of CD300f. Importantly, intranasal administration of ceramide liposomes reduced the frequency of sneezing as well as the numbers of degranulated mast cells and eosinophils in the nasal tissues in AR models. Thus, CD300f-ceramide interaction, predominantly in mast cells, alleviates the symptoms and progression of AR. Therefore, intranasal administration of ceramide liposomes may be a promising therapeutic approach against AR by targeting CD300f.
The invention relates to a process for extracting and separating lilac iridoid glycoside. Lilac leaves are aqueously extracted, condensed by depressurization, defecated in chitosan, deposited in ethanol, filtered, centrifugally separated, absorbed by macroporous adsorbing resin, and eluted with ethanol; ethanol is recycled from eluent; the filter liquor is extracted by ethyl acetate, and is separated through a millipore filter before the filter liquor is extracted and separated with silicagel columns; gradient elution is conducted with chloroform and methanol; solvent is recycled from the eluent. The thin-layer chromatography is used for detecting lilac iridoid glycoside, and the high efficiency liquid chromatography is used for measuring the lilac iridoid glycoside with the purity larger than 90 percent. The process provided by the invention is simple and designed reasonably. The product obtained through the process can meet medicinal requirement. The lilac iridoid glycoside has the functions of antibiosis, diminishing inflammation and antivirus, and can inhibit golden yellow Staphylococcus, Bacillus dysenteriae, colibacillus, Pseudomonas aeruginosa and so on. The process is used for curing such diseases as upper respiratory tract infection, bacillary dysentery and so on.
Triple Combination Therapy with bimatoprost/brimonidine tartrate/timolol ophthalmic solution. One drop of Triple Combination Therapy administered to each eye, twice daily for up to 12 months.
FIELD: pharmaceutical industry, technical entomology. SUBSTANCE: method involves sorption of mixture of ecdysteroids from solution on hydrophobic sorbents to obtain the limit capacity by ecdysone followed by their desorption. Desorption is carried out from an aqueous-organic solution. Invention is designated for preparing individual ecdysteroids from their mixture. EFFECT: enhanced output, decreased energy consumption. 1 ex
To probe the understanding of healthcare providers regarding occupational exposure to human papillomavirus and their knowledge about human papillomavirus vaccination in relation to the American Society for Colposcopy and Cervical Pathology (ASCCP) recommendations. In this cross-sectional study, the healthcare providers at Mayo Clinic Arizona, Florida, and Minnesota were delivered an electronic survey. The survey was completed by 349 healthcare providers, with one respondent excluded for inconsistent entry. The mean age of respondents was 42.7 ± 10.9, and of those, 68% were female and 32% were male. Of the unvaccinated respondents, 43.3% were ≤ 45 y of age (eligible for vaccination), while those vaccinated formed 41% of the respondents. Healthcare providers are highly concerned about their cancer safety, as shown by their awareness of occupational human papillomavirus hazards and broad knowledge about vaccine efficacy. The use of personal protective equipment varied widely, including eyewear, double gloving, procedural face mask, N95 face mask, and/or nothing. Human papillomavirus and cancer risk was clearly perceived by healthcare providers. For professions, pairwise comparisons revealed that nurse practitioners, physician assistants, certified registered nurse anesthetists, and allied healthcare providers had lower scores than medical doctors. Despite the high level of understanding among healthcare providers of occupational human papillomavirus exposure, only a few of them knew of the recommendations of the ASCPP for vaccination of healthcare providers treating human papillomavirus-related diseases. In such cases, most of those surveyed embraced vaccination, which was considered 100% safe by medical doctors and allied health professionals.
Communities randomized to education only will be provided with staff education using our developed Powerpoint for Component II of the PAIN-CPG-EIT intervention in 30 minute sessions as is currently done in usual practice. They will also be given access to an online copy of the Pain Management CPG. The education will be provided in the preferred format (e.g., face-to-face; webinar).
<P>PROBLEM TO BE SOLVED: To provide a material which is a nonwoven sheet using cellulose nano-fibers, and having performances of gradually degrading under the natural environment and finally disappearing after use without causing air pollution when incinerated after the use with less effects on the environment, and having a soft touch feeling and a good touch on skin.  <P>SOLUTION: The nonwoven sheet comprises the cellulose nano-fibers as main fibers. The main fibers are mutually heat-bonded by softening or melting a binder component of the binder fibers. The binder component is a polymer obtained by copolymerizing a polyalkylene succinate with at most 10 mol% of lactic acid. The binder fibers are preferably core-sheath type conjugated fibers in which a polylactic acid is arranged in a core part and a polymer that is prepared by copolymerizing the polyalkylene succinate with at most 10 mol% of the lactic acid is arranged in a sheath part.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Vorinostat 300 mg once a day for 3 days a week + erlotinib 150 mg once a day was evaluated in the Phase I portion of the amended study and exceeded the MTD. All patients treated at this dose level were assigned to the Phase I portion of the study.
The invention provides a Vero cell cold-adapted strain of influenza A virus and an application thereof. The Vero cell cold-adapted strain is named as A/Yunnan/1/2005Vca (H3N2), the microbial preservation number is CCTCC NO. V201253. The strain can be subjected to a continuous passage culture on a Vero cell, the hemagglutination titer is maintained at 1:512-1:1024, and the infectious titer is maintained at 7.0-8.5log10TCID50/ml, and has phenotypes of Ca and Ts and characteristics of Att by identification. The strain as a female parent strain and an epidemic strain is subjected to a genetic reassortment, or six internal genes of the strain and two surface protein genes of the epidemic strain are subjected to a gene reassortment by a reverse genetics technology to obtain the Vero cell cold-adapted strain containing surface antigens of the epidemic strain. The Vero cell cold-adapted strain can be used in the preparation of Vero cell live-attenuated influenza vaccines or live-attenuated influenza vaccines, and can be also used for the production of inactivated influenza vaccines.
Argon fulguration will be performed using CO2 for insufflation. After using a disposable endoscopic catheter, argon plasma (Argon 2) (MAE, Ribeirão Preto, Brazil) will be applied in a 1-cm band around the entire circumference of the gastrojejunal anastomosis at an intensity of 90 W and a flow rate of 2 L/min.
Volunteers from this group will have bonded buttons on vestibular surfaces of elements 1.4, 1.5 and 1.6. Then they will use Biorepair Total Protection for home oral care for 30 days. In this time period, the buttons will be respectively debonded at 7 (1.4), 15 (1.5) and 30 (1.6) days after the bonding procedures, in order to be evaluated at SEM.
Emactuzumab and RO7009789 will be administered IV at the maximum tolerated dose defined in Part I of the study. Treatment will continue as long as there is clinical benefit until unacceptable toxicity, symptomatic deterioration, or withdrawal of consent.
PROBLEM TO BE SOLVED: To obtain the subject medicinal agent containing a silicic acid polymer as active ingredient, having such biological function regulative effect as to restore and normalize the abnormalities of biological function developed in morbid state, thus useful for preventing/treating allergic diseases and gastritis, etc. SOLUTION: This medicinal agent contains a silicic acid polymer as active ingredient. The polymer is pref. a water-soluble silicic acid polymer 20,000-1,000,000 in molecular weight and 490-16,500 in polymerization degree, and can be obtained, for example, by dissolving a water-soluble silicate such as sodium orthosilicate, or a silicic acid-contg. substance such as water-glass in an aqueous solvent followed by adjustment to pH 2-10 and then evaporation to dryness under heating or lyophilization followed by pulverization. In this case, it is preferable that a saccharide such as lactose or mannitol is added to the resulting aqueous solution. The daily dose of this agent is normally 1μg to 10mg/adult in terms of silicic acid in one to several portions.
INTRODUCTION: Cortico-cortical evoked potentials (CCEPs) were described as reproducible during trains of single-pulse electrical stimulations (SPES). Still, few studies described a variability of CCEPs that was higher within the epileptogenic zone (EZ). This study aimed at characterizing the relationship of CCEP variability with the occurrence of interictal/ictal epileptiform discharges at the temporal vicinity of the stimulation, but not during the stimulation, by effective connectivity modifications.
METHODS: We retrospectively included 20 patients who underwent SPES during their stereo-electroencephalography (SEEG). We analyzed the variability of CCEPs by using the post-stimulation time course of intertrial standard deviation (amplitude) and the timing of peak amplitude signal of CCEP epochs (latency). Values were corrected for the Euclidian distance between stimulating/recording electrodes. Receiver operating characteristics curves were used to assess the relationship with the EZ. The link between CCEP variability and interictal discharges occurrence, seizure frequency prior to the SEEG recording, and number of seizures during SEEG recording was assessed with Spearman's correlations.
RESULTS: A relationship was demonstrated between the EZ and both the distance-corrected latency variation (area under the curve (AUC): 0.73-0.74) and the distance-corrected amplitude variation (AUC: 0.71-0.72) and both were related with the occurrence of seizures.
CONCLUSION: Seizures before/during SEEG impact the dynamics of effective connectivity within the epileptogenic network by reducing the variability of CCEP latency/amplitude when the seizure frequency increases. It suggests a strengthening of the epileptogenic network with the occurrence of many seizures. These findings stress the importance of early epilepsy surgery at a time when the network organization has not yet been complete.
A method for controlling the epimerization of (-)-epicatechin to (-)-catechin in an epicatechin-containing product, preferably an edible product, or of (+)-catechin to (+)-epicatechin in a catechin-containing product, comprises the step of heating the product at a temperature of up to about 200° C and at a pH of up to about 8. Under either method, the epimerization may be carried out in an open food processor in a reduced oxygen atmosphere or in a closed food processor. The edible product may be pasteurized, boiled, or sterilized during the epimerization. Epimerization is minimized by lowering the heating temperature, by lowering the pH, and/or by lowering the heating time. Conversely, the epimerization is maximized by increasing the heating temperature, by increasing the pH, and/or by increasing the heating time. The edible product may contain or be a fruit product, a vegetable product, a cereal product, a bean product, a nut product, a spice product, or a botanical product.
The invention provides a Cu-metformin complex with an antibacterial effect, a crystal structure thereof, a preparation method and application, wherein the Cu-metformin complex has a structure shown in a formula I. The invention uses metformin hydrochloride and CuSO 4 ·5H 2 The coordination effect of O precise positioning constructs a novel three-dimensional Cu-metformin complex. The invention evaluates the bacteriostatic activity of metformin hydrochloride and Cu-metformin complex on gram-positive bacteria and gram-negative bacteria (such as staphylococcus aureus, escherichia coli and the like). Research shows that metformin hydrochloride has no bacteriostatic activity and is mixed with CuSO 4 ·5H 2 The Cu-metformin complex formed after O coordination obtains good bacteriostatic activity. The invention realizes the transformation of the bacteriostatic activity of the compound from nothing to nothing. The Cu-metformin complex provided by the application can obviously improve the drug resistance problem of the existing antibiotics and has higher safety.
PURPOSE OF REVIEW: Acute kidney injury (AKI) is a frequent and serious complication in critically ill patients. Currently, no effective therapy to prevent or treat AKI is available. This review highlights recently published developments on pharmacological treatments that aim to prevent AKI or to alleviate the severity of AKI in critical ill patients.
RECENT FINDINGS: Studies on pharmacological interventions aimed to improve hemodynamics, renal perfusion, to mediate inflammation-associated renal damage and to reduce oxidative stress are presented, including several observational studies and randomized trials focused on the potential renal protective effects in relevant patient populations. Different existing and novel compounds are being investigated for the effects on renal endpoints and several show potential to prevent or alleviate the occurrence of AKI. It is now acknowledged that different underlying pathophysiological processes are relevant in the development of AKI. Recognition of these sub-endotypes of AKI and knowledge of the therapeutic target of different compounds is of paramount importance to select the right patient for the right treatment at the right time.
SUMMARY: The discovery of reno-protective therapies is hampered by the timely detection and recognition of the overriding mechanism of AKI. Nevertheless, several compounds are under investigation, which hold promise for a future treatment.
SHAKE WELL BEFORE USING. Two drops topically in the affected eye(s) four times daily. In cases of bacterial infections, concomitant use of anti-infective agents is mandatory. Care should be taken not to discontinue therapy prematurely. If signs and symptoms fail to improve after two days, the patient should be reevaluated (see PRECAUTIONS).

The dosing of prednisolone acetate ophthalmic suspension may be reduced, but care should be taken not to discontinue therapy prematurely. In chronic conditions, withdrawal of treatment should be carried out by gradually decreasing the frequency of applications.
The invention discloses a Chinese medicine preparation for treating hyperuricemia, relating to the field of traditional Chinese pharmacology. The Chinese medicine preparation is prepared from the following medicinal materials, by weight: 30 to 45 g Poria cocos, 9 to 12 g amur corktree barks, 12 to 15 g Atractylodes sinenisis rhizomes, 24 to 30 g Dioscorea hypoglauca rhizomes, 24 to 30 g Smilax glabra  rhizomes, 24 to 30 g psyllium seeds, 24 to 30 g oriental water plantain rhizomes, 24 to 30 g coix seeds, 30 to 45 g Astragalus roots, 9 to 12 g wine-treated rhubarb roots, 3 to 6 g leech powder, 24 to 30 g giant knotweed rhizomes, 12 to 15 g parched hawthorn fruits, 12 to 15 g lotus leaves, 12 to 15 g cassia seeds, 12 to 15 g white peony roots, and 3 to 6 g raw licorice. To sum up, the 17 Chinese medicines used in the Chinese medicine preparation are cheap and can be made into different dosage forms with common methods. The prepared Chinese medicine preparation has only a little toxic and side effect. While using the Chinese medicine preparation for treatment, adverse, allergic and toxic reactions induced by western medicines, such as benzbromarone, allopurinol and the like, can be avoided. The Chinese medicine preparation is absorbed easily and quickly in alimentary canals, and has a short treatment course and a high cure rate.
The invention comprises carbocyclic hydroxyamines of the formula <FORM:1023214/C2/1> in which R1 is H, alkyl containing at least 2 carbon atoms, R2 is H, alkyl containing at least 2 carbon atoms, hydroxy alkyl, alkoxy alkyl, cycloalkyl, alkenyl, aralkyl or haloalkyl, n is 1 or 2 and in which the carbocyclic nucleus may optionally bear one or more halogen, hydroxy, alkyl or alkoxy substituents, their carboxylic esters and salts thereof.  The esters are preferably those of acids of formula R3COOH in which R3 is an alkyl, alkenyl or aryl radical of not more than 20 carbon atoms. The hydroxyamines may be made as follows:-(a) by reacting a halogeno compound of formula <FORM:1023214/C2/2> in which X is a halogen, with an amino of formula NHR1R2; (b) by reacting an epoxide of formula <FORM:1023214/C2/3> with an amine of formula NHR1R2; (c) by reactin a compound of formula <FORM:1023214/C2/4> with a compound of formula XCH2.CHOH.CH2.NR1R2 or <FORM:1023214/C2/5> (d) when R1 is H and R2 is a radical of formula -CHR4R5 in which R4 is H or alkyl and R5 is alkyl, hydroxyalkyl, alkoxyalkyl, alkenyl, aralkyl, or haloalkyl, by reacting a compound of formula <FORM:1023214/C2/6> with a carbonyl compound of formula R4COR5 under reducing conditions, e.g. in the presence of hydrogen and a hydrogenation catalyst; (e) when n is 2, by the reduction of a naphthalene derivative of formula <FORM:1023214/C2/7> or (f) when R1 is hydrogen by the hydrogenolysis of a compound of formula <FORM:1023214/C2/8> in which R6 is a radical capable of being removed by hydrogenolysis.  The carboxylic esters of these compounds may be produced by treatment with acylating agents, e.g. acetic anhydride, acetyl chloride or benzoyl chloride. The salts may be acid addition salts of inorganic acids, e.g. hydrochlorides, hydrobromides, phosphates and sulphates or of organic acids, e.g. oxalates, lactates, tartrates, acetates, salicylates, citrates, benzoates, naphthoates, o-acetoxybenzoates, adipates, maleates and 1,11-methylene - bis - (2 - hydroxy - 3 - naphthoates), or of acidic synthetic resins.  Starting materials of formulae <FORM:1023214/C2/9> or <FORM:1023214/C2/100> are prepared by reacting the corresponding hydroxy substituted carbocyclic compound with epichlorhydrin in the presence of piperidine or caustic soda.  The new carbocyclic hydroxyamines referred to above may be incorporated into pharmaceutical compositions for the treatment of coronary artery disease.  The active compounds may be used in association with a pharmaceutically-acceptable diluent or carrier and may be administered orally or by injection.
<P>PROBLEM TO BE SOLVED: To provide a collagen production promoter comprising a plant-derived component that promotes production of collagen from collagen production cells and is friendly to the body, a cosmetic and an oral composition for collagen production promotion.  <P>SOLUTION: The collagen production promoter comprises a seed extract of passion fruit as an active ingredient. Preferably the seed extract of passion fruit is extracted with hot water or ethanol-containing water. The cosmetic comprises the seed extract of passion fruit. The seed extract of passion fruit is made into a product as an oral composition for collagen production promotion.  <P>COPYRIGHT: (C)2009,JPO&INPIT
The new compounds cadmium butanesulphonate, cadmium p-carbomethoxybenzenesulphonate, cadmium p-carboxybenzenesulphonate, cadmium methanesulphonate, cadmium p-anisylsulphonate, cadmium p-nitrobenzenesulphonate, cadmium 2-propylsulphonate and cadmium p-thioanisylsulphonate are prepared by adding cadmium oxide to a hot stirred aqueous solution of the sulphonic acid using the theoretical molar ratio of the reactants or a slight excess of the acid.  The hydrated salts thus obtained may be dehydrated by vacuum drying.ALSO:Anthelmintic compositions suitable for administration to pigs comprise a water-soluble camdium salt of a sulphonic acid and a physiologically acceptable organic or inorganic acid in an amount sufficient to give in solution a pH of from 3 to 6.5.  The salts may be aromatic salts of the formula <FORM:0932962/VI/1> wherein R2 is a hydrogen or halogen atom or a lower (C1-8) alkyl or alkoxy, hydroxy, amino, nitro, carboxy, carbalkoxy or mercapto or lower alkyl thio radical or aliphatic salts of the formula [R1-SO3]2Cd, wherein R1 is a straight or branched chain C1-6 alkyl radical. Suitable acids are hydrochloric, sulphuric, acetic, citric, lactic, benzoic, p-toluene sulphonic and benzene and methane sulphonic acids.  The compositions may be in the form of solid or aqueous concentrates and may also contain flavouring agents and nutritional factors, e.g. one or all of the b -vitamins.  The preparation of several new cadmium sulphonates is described (see Group IV (b)).
Intraoperative hypothermia is one of the most common adverse events related to surgery, and clinical practice has been severely underestimated. In view of this, this study aims to build a practical intraoperative hypothermia prediction model for clinical decision-making assistance. We retrospectively collected clinical data of patients who underwent gynecological laparoscopic surgery from June 2018 to May 2023, and constructed a multimodal algorithm prediction model based on this data. For the construction of the prediction model, all data are randomly divided into a training queue (70%) and a testing queue (30%), and then 3 types of machine learning algorithms are used, namely: random forest, artificial neural network, and generalized linear regression. The effectiveness evaluation of all predictive models relies on the comprehensive evaluation of the net benefit method using the area under the receiver operating characteristic curve, calibration curve, and decision curve analysis. Finally, 1517 screened patients were filtered and 1429 participants were included for the construction of the predictive model. Among these, anesthesia time, pneumoperitoneum time, pneumoperitoneum flow rate, surgical time, intraoperative infusion, and room temperature were independent risk factors for intraoperative hypothermia and were listed as predictive variables. The random forest model algorithm combines 7 candidate variables to achieve optimal predictive performance in 2 queues, with an area under the curve of 0.893 and 0.887 and a 95% confidence interval of 0.835 to 0.951 and 0.829 to 0.945, respectively. The prediction efficiency of other prediction models is 0.783 and 0.821, with a 95% confidence interval of 0.725 to 0.841 and 0.763 to 0.879, respectively. The intraoperative hypothermia prediction model based on machine learning has satisfactory predictive performance, especially in random forests. This interpretable prediction model helps doctors evaluate the risk of intraoperative hypothermia, optimize clinical decision-making, and improve patient prognosis.
Participants will be randomized to the usual care group (N=34). Participants in this group will resume to their usual standard of care for 8 weeks.